FI952930A7 - Pysyvien sinkki-insuliinianalogikiteiden valmistaminen - Google Patents

Pysyvien sinkki-insuliinianalogikiteiden valmistaminen Download PDF

Info

Publication number
FI952930A7
FI952930A7 FI952930A FI952930A FI952930A7 FI 952930 A7 FI952930 A7 FI 952930A7 FI 952930 A FI952930 A FI 952930A FI 952930 A FI952930 A FI 952930A FI 952930 A7 FI952930 A7 FI 952930A7
Authority
FI
Finland
Prior art keywords
preparation
insulin analog
zinc insulin
stable zinc
analog crystals
Prior art date
Application number
FI952930A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI952930L (fi
FI952930A0 (fi
Inventor
Jeffrey Clayton Baker
Nancy Delores Carter
Bruce Hill Frank
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22990041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI952930(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI952930A0 publication Critical patent/FI952930A0/fi
Publication of FI952930L publication Critical patent/FI952930L/fi
Publication of FI952930A7 publication Critical patent/FI952930A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI952930A 1994-06-16 1995-06-14 Pysyvien sinkki-insuliinianalogikiteiden valmistaminen FI952930A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,647 US5504188A (en) 1994-06-16 1994-06-16 Preparation of stable zinc insulin analog crystals

Publications (3)

Publication Number Publication Date
FI952930A0 FI952930A0 (fi) 1995-06-14
FI952930L FI952930L (fi) 1995-12-17
FI952930A7 true FI952930A7 (fi) 1995-12-17

Family

ID=22990041

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952930A FI952930A7 (fi) 1994-06-16 1995-06-14 Pysyvien sinkki-insuliinianalogikiteiden valmistaminen

Country Status (29)

Country Link
US (1) US5504188A (cg-RX-API-DMAC10.html)
EP (1) EP0692489B1 (cg-RX-API-DMAC10.html)
JP (1) JP3595607B2 (cg-RX-API-DMAC10.html)
KR (1) KR100369951B1 (cg-RX-API-DMAC10.html)
CN (1) CN1184234C (cg-RX-API-DMAC10.html)
AT (1) ATE233278T1 (cg-RX-API-DMAC10.html)
AU (1) AU697794B2 (cg-RX-API-DMAC10.html)
BR (1) BR9502798A (cg-RX-API-DMAC10.html)
CA (1) CA2151563C (cg-RX-API-DMAC10.html)
CO (1) CO4410205A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ286066B6 (cg-RX-API-DMAC10.html)
DE (1) DE69529708T2 (cg-RX-API-DMAC10.html)
DK (1) DK0692489T3 (cg-RX-API-DMAC10.html)
ES (1) ES2188637T3 (cg-RX-API-DMAC10.html)
FI (1) FI952930A7 (cg-RX-API-DMAC10.html)
HU (1) HUT73495A (cg-RX-API-DMAC10.html)
IL (1) IL114152A (cg-RX-API-DMAC10.html)
IN (1) IN178919B (cg-RX-API-DMAC10.html)
MY (1) MY130551A (cg-RX-API-DMAC10.html)
NO (1) NO952334L (cg-RX-API-DMAC10.html)
NZ (1) NZ272358A (cg-RX-API-DMAC10.html)
PE (1) PE21896A1 (cg-RX-API-DMAC10.html)
PL (1) PL180968B1 (cg-RX-API-DMAC10.html)
RO (1) RO113529B1 (cg-RX-API-DMAC10.html)
RU (1) RU2156257C2 (cg-RX-API-DMAC10.html)
SI (1) SI0692489T1 (cg-RX-API-DMAC10.html)
TW (1) TW379228B (cg-RX-API-DMAC10.html)
YU (1) YU39595A (cg-RX-API-DMAC10.html)
ZA (1) ZA954942B (cg-RX-API-DMAC10.html)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
DE69806582T2 (de) * 1997-03-20 2003-02-13 Novo Nordisk A/S, Bagsvaerd Verfahren zur herstellung eines therapeutischen puders durch copräzipitation von insulin und einem absorptionsverstärker
AU1375199A (en) * 1997-11-12 1999-05-31 Alza Corporation Method for decreasing self-association of polypeptides
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
IL142002A0 (en) * 1998-10-16 2002-03-10 Novo Nordisk As Insulin preparation for pulmonary delivery containing menthol
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
HUP0104111A3 (en) * 1998-10-16 2002-05-28 Novo Nordisk As Stable concentrated insulin preparations for pulmonary delivery
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
CN1406131A (zh) * 2000-12-25 2003-03-26 株式会社资生堂 活化交感神经的香料组合物
NZ548359A (en) * 2001-02-09 2007-11-30 Genentech Inc Method of identifying indirect agonists of insulin-like growth factor-1
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
JP4563675B2 (ja) 2001-10-12 2010-10-13 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 置換ピペリジン類、およびヒスタミンｈ３受容体関連疾患の治療のためのその使用
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
CN1882356B (zh) 2003-11-20 2015-02-25 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
MX2007001589A (es) * 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
KR101286569B1 (ko) 2005-07-04 2013-07-23 하이 포인트 파마슈티칼스, 엘엘씨 신규 약제
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
EP1951658B1 (en) 2005-11-17 2012-09-26 Eli Lilly & Company Glucagon receptor antagonists, preparation and therapeutic uses
US20090054305A1 (en) 2006-03-15 2009-02-26 Novo Nordisk A/S Mixtures of Amylin and Insulin
AU2007229492B2 (en) 2006-03-28 2011-11-03 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
ES2378574T3 (es) 2006-04-24 2012-04-16 Eli Lilly & Company Pirrolidinonas ciclohexilo substituidas como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
CN102295606A (zh) 2006-05-29 2011-12-28 高点制药有限责任公司 合成3-（1，3-苯并间二氧杂环戊烯-5-基）-6-（4-环丙基哌嗪-1-基）-哒嗪的方法及其适用的中间体
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2164459A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
WO2008145728A1 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
ES2744384T3 (es) * 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
JP5868594B2 (ja) * 2007-10-16 2016-02-24 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ 経口投与可能な固形医薬組成物及びそのプロセス
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
EP2337563B1 (en) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
EA020496B1 (ru) 2008-11-21 2014-11-28 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Производное адамантилбензамида, фармацевтическая композиция, включающая его, и его применение
EP2391217A4 (en) 2009-01-28 2015-05-20 Smartcells Inc SYNTHETIC CONJUGATES AND ITS USE
MX2011007929A (es) 2009-01-28 2011-08-17 Smartcells Inc Sistemas basados en conjugados para entrega farmacologica controlada.
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
MY186089A (en) * 2009-08-11 2021-06-21 Biocon Ltd Chromatographic processes and purified compounds thereof
EP2670773A1 (en) 2011-02-01 2013-12-11 Novo Nordisk A/S Purification of insulin
EP2670368A4 (en) 2011-02-03 2015-04-15 Pharmedica Ltd NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
CN103342746B (zh) * 2013-07-26 2014-07-30 珠海联邦制药股份有限公司 一种制备稳定的门冬胰岛素结晶的方法
WO2015084694A2 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
EP2990033A1 (fr) * 2014-08-26 2016-03-02 Carlina Technologies Procédé de préparation de nanoprécipites de peptide ou protéine de faible poids moléculaire
EP3185887B1 (en) 2014-08-26 2021-03-10 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
CN104193819B (zh) * 2014-09-03 2017-05-17 韩飞 胰岛素二聚体晶体的合成和保存方法
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CN104892749B (zh) * 2015-06-16 2019-02-05 珠海联邦制药股份有限公司 一种德谷胰岛素结晶的制备方法及应用
CN105753966A (zh) * 2016-05-05 2016-07-13 通化东宝药业股份有限公司 一种重组人胰岛素结晶的制备方法
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
MX2022012208A (es) 2020-03-31 2022-12-15 Protomer Tech Inc Conjugados para reactividad selectiva a dioles vecinales.
CA3198757A1 (en) 2020-11-19 2022-05-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品
AU2023272483A1 (en) 2022-05-18 2024-12-12 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE515508A (cg-RX-API-DMAC10.html) *
BE533252A (cg-RX-API-DMAC10.html) *
BE533298A (cg-RX-API-DMAC10.html) *
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2920104A (en) 1958-07-01 1960-01-05 Vanderbilt Co R T Stabilized solutions of a dithiocarbamate
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
FI910286A0 (fi) * 1988-07-20 1991-01-18 Nordisk Gentofte Analoger av humant insulin och preparat innehaollande dessa.
JPH04502465A (ja) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
KR100310122B1 (ko) * 1993-09-17 2002-04-24 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 아실화된인슐린
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas

Also Published As

Publication number Publication date
CZ154195A3 (en) 1996-02-14
PL309099A1 (en) 1995-12-27
PE21896A1 (es) 1996-06-15
FI952930L (fi) 1995-12-17
DK0692489T3 (da) 2003-03-31
MY130551A (en) 2007-06-29
YU39595A (sh) 1997-08-22
IN178919B (cg-RX-API-DMAC10.html) 1997-07-19
JP3595607B2 (ja) 2004-12-02
TW379228B (en) 2000-01-11
KR100369951B1 (ko) 2003-03-28
KR960000922A (ko) 1996-01-25
EP0692489A1 (en) 1996-01-17
CN1128271A (zh) 1996-08-07
ES2188637T3 (es) 2003-07-01
SI0692489T1 (en) 2003-06-30
ZA954942B (en) 1996-12-17
CO4410205A1 (es) 1997-01-09
DE69529708D1 (de) 2003-04-03
JPH08169899A (ja) 1996-07-02
CA2151563A1 (en) 1995-12-17
CA2151563C (en) 2007-08-07
ATE233278T1 (de) 2003-03-15
RO113529B1 (ro) 1998-08-28
NZ272358A (en) 1996-12-20
PL180968B1 (pl) 2001-05-31
FI952930A0 (fi) 1995-06-14
EP0692489B1 (en) 2003-02-26
CZ286066B6 (cs) 2000-01-12
IL114152A (en) 1999-12-31
NO952334L (no) 1995-12-18
AU2168195A (en) 1996-01-04
CN1184234C (zh) 2005-01-12
RU2156257C2 (ru) 2000-09-20
HU9501715D0 (en) 1995-08-28
US5504188A (en) 1996-04-02
BR9502798A (pt) 1996-06-04
DE69529708T2 (de) 2003-10-16
HUT73495A (en) 1996-08-28
AU697794B2 (en) 1998-10-15
RU95110107A (ru) 1997-05-10
IL114152A0 (en) 1995-10-31
NO952334D0 (no) 1995-06-13

Similar Documents

Publication Publication Date Title
FI952930A7 (fi) Pysyvien sinkki-insuliinianalogikiteiden valmistaminen
FI952932A0 (fi) Monomeeriset insuliinianalogivalmisteet
DK67795A (da) Insulinanalog-formuleringer
FI954541A7 (fi) Keratinosyyttikasvutekijän terapeuttisia käyttöjä
ZA908817B (en) Stable oral composition of zinc
FI960750L (fi) Hermon kasvutekijän farmaseuttiset formulaatiot
ATE198275T1 (de) Subkutane implantate bestehend aus nomgestrolderivaten
EP0709395A3 (en) Preparation of Stable Insulin Analog Crystals
BR9610821A (pt) Derivado de aminoácido uso de um composto e medicamento contendo o mesmo
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
IL85777A0 (en) Preparation of algae having improved biological effects
ZA89807B (en) Use of keto group-containing cyclic compounds
IL88394A0 (en) Heterocyclic compounds and their use as insecticides
FI911644A7 (fi) Terapeuttinen yhdiste ja koostumus
EP0454485A3 (en) Expression of insecticidal proteins
FI910207A0 (fi) Fungisidisia vaikuttavien aineiden yhdistelmiä
ZA935647B (en) Treatment of sickle cell disease
AU7859391A (en) Crystals of factor d
DK137191A (da) Insulinpraeparat
DE59502325D1 (de) Arzneimittelszusammensetzung aus S-Milchsäure und dessen Verwendung
DE69316336D1 (de) Insektizide und akarizide zusammensetzung
DE68925723D1 (de) Pyrazol-Verbindungen und ihre Herstellung und Verwendung
AU4972693A (en) Use of carrageenans as growth factor antagonists
SE9200678D0 (sv) Use of human growth hormone
AU8985791A (en) Transdermal delivery of dobutamine